RxDoctor Payments Data

Juanita Mora, MD

Allergy & Immunology · Chicago, ILNPI 1750557179

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 44.7% of the total. Among allergy & immunology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$146,635in general payments, 2019–2025

Across 1,045 payments — averaging $140.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$66K
  • GSK$52K
  • AstraZeneca$10K
  • Sanofi$7K
  • Regeneron Healthcare Solutions, Inc.$3K
  • Novartis$2K
  • plus $7K from 28 others

What the payments were for

  • Consulting fees$75,08851%
  • Speaking & faculty fees$40,74528%
  • Travel & lodging$7,8145%
  • Food & beverage$22,93116%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,635 in reported general payments places this provider in the 95th percentile of 161 allergy & immunology providers in Illinois.

See all allergy & immunology providers in Illinois

Medicare billing

Part B allowed, 2024
$38,463
Medicare patients
68
Services billed
3,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko14$57,055
XolairOmalizumab17$43,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,282
Fluticasone Propionate169$2,558
Montelukast Sodium205$1,752
Ventolin HfaAlbuterol Sulfate25$1,460
Albuterol Sulfate HfaAlbuterol Sulfate38$1,145
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$887
Hydroxyzine Hcl57$537
Prednisone188$507
Levocetirizine Dihydrochloride22$235
Triamcinolone Acetonide29$228
Doxepin Hcl11$208
Azithromycin67$175
Levofloxacin13$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire$10,435$57,05514 claims
Genentech, Inc.Xolair$54$43,19817 claims
GSKTrelegy Ellipta$51,921$13,28217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 allergy & immunology providers in Illinois.

Other allergy & immunology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →